InterCure Ltd. (INCR) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

InterCure Ltd.

INCR

NASDAQ

75M

Drug Manufacturers - Specialty & Generic

1.61USD

-0.02 ( -1.20%)

Market Open

Relative Strenght

82

Volume Buzz

-22%

Earning Acce

No

Dist 52w H.

57%

Quote Panel

Updated March 18, 2025

1W 1.27 % 1M -0.62 % 3M 19.40 % 1Y -20.00 %

Key Metrics

Market Cap
75.46M
Shares Outstanding
47.16M
Share in Float
26.54M
Dividende
0

Earning Date
No Data
Price Target
1.6
Average Volume
30334
Beta
0.103

Range
1.17-3.72
Industry
Drug Manufacturers - Specialty & Generic
Website
https://www.intercure.co
Sector
Healthcare

Fundamentals

Relative Strength

INCR

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$1B

1838%

2024-Revenue

0

$307M

-4368%

2024-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Canaccord Genuity

upgrade

Previous: Not converted

2022-05-17

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q2.22

-17%

0.1
vs 0.12

Q3.22

+600%

0.05
vs -0.01

Q4.22

+350%

0.05
vs -0.02

Q1.23

-91%

0.01
vs 0.11

Q2.23

-70%

0.03
vs 0.1

Q3.23

N/A

0.05
vs 0.05

Q4.23

N/A

0.05
vs 0.05

Q1.24

-59%

0
vs 0.01

Q2.24

-87%

0
vs 0.03

Q3.24

+11573%

5.84
vs 0.05

Sales Growth

YoY

Current

Estimates

Q2.22

+111%

95.3M vs 45.2M

Q3.22

+63%

100.6M vs 61.7M

Q4.22

+33%

105.6M vs 79.7M

Q1.23

+22%

106.2M vs 87.2M

Q2.23

+8%

102.4M vs 95.3M

Q3.23

-27%

73.5M vs 100.6M

Q4.23

-30%

73.5M vs 105.6M

Q1.24

-41%

62.9M vs 106.2M

Q2.24

-39%

62.9M vs 102.4M

Q3.24

-3%

71.5M vs 73.5M

Return on Equity

QoQ

Q3.22

+1%

0.01
vs 0.03

Q4.22

+1%

0.01
vs 0.01

Q1.23

+0%

0
vs 0.01

Q2.23

+1%

0.01
vs 0

Q3.23

-7%

-0.07
vs 0.01

Q4.23

-7%

-0.07
vs -0.07

Q1.24

+0%

0
vs -0.07

Q2.24

+0%

0
vs 0

Institutionnal Ownership

QoQ

Q1.23

18

18
vs 16

13%

Q2.23

19

19
vs 18

6%

Q3.23

22

22
vs 19

16%

Q4.23

18

18
vs 22

-18%

Q1.24

20

20
vs 18

11%

Q2.24

20

20
vs 20

NA

Q3.24

21

21
vs 20

5%

Q4.24

18

18
vs 21

-14%

Earnings Growth

Latest News

INCR

seekingalpha.com

3 hours ago

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

INCR

prnewswire.com

8 hours ago

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

INCR

businesswire.com

8 hours ago

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

INCR

benzinga.com

14 hours ago

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

INCR

prnewswire.com

18 hours ago

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

INCR

globenewswire.com

18 hours ago

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million